Disclosed is the use of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile (as pictured) in the manufacture of a medicament, when the medicament is adapted to provide a weekly dose of more than 250mg of the compound. Also disclosed a pharmaceutical composition formulated in a single dose form comprising more than 250 mg of the compound. The medicament can be used to treat diabetes.